Cangrelor Case Presentations

Slides:



Advertisements
Similar presentations
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Advertisements

The Macstrak Project CCU Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
ACS and Thrombosis in the Emergency Setting
Amy Gutman MD EMS Medication Director
Unstable angina and arterial hypertension Leszek Kinasz, MD American Heart of Poland Ustron, Poland.
Medical Grand Rounds Clinical Vignette October 15 th, 2008 Srikant Duggirala, M.D.
TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.
Clinical Correlations The NYU Langone Online Journal of Medicine
One patient, two years, three choices, four PCI ZHAO Peng Cardiology , the Affiliated Hospital of Medical College of CPAPF, Tianjin, China.
Diagnosis, Management, & Follow-up Care Of CAD/AMI BARRY BERTOLET, MD CARDIOLOGY ASSOCIATES OF NORTH MS.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
CASE PRESENTATION Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease.
Acute Coronary Syndrome
Transradial Best Practices for Radial Access
Simplifying Serial Lesion Assessment
CPR in ACUTE CORONARY SYNDROM
Interesting-Didactic Cases
SFGH Criteria for STEMI Activation
Objectives Review chest pain Define ACS
Adel Gamal, MD and Mohamed Saber, Msc
Pharmacotherapy Update for STEMI: What Is New?
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Nightmares in the Cath Lab
Risk Stratification of Chest Pain: Best Practices
Abed Dehnee MD, Rajiv Patel MD, Dan Tsyvine MD, Edo Kaluski, MD
LAAO with Watchman Device Post-Procedure Best Practices
Interesting Case Presentation
Should We Preload STEMI Patients with Antiplatelet Therapy?
Guideliner related stent stripping
Clinical Presentation
T1: ACS Treatment Tutoring
Tarek Abou Ghazala, MD, FACC, FSCAI
T1: Post ACS Treatment Tutoring
CRT 2017 Interventional Challenging Case Anterior ST- Elevation Myocardial Infarction Resulting From Acute Occlusion of Left Internal Mammary Artery Graft.
The Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel
Antiplatelet therapy for STEMI
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Crescendo angina in Distal Left Main CTO
Ischaemic Heart Disease Acute Coronary Syndrome
Fractional Flow Reserve Workshop
2014 NSTE-ACS Guidelines Andrew Seier, MS4.
Preventing Thrombotic Complications in ACS: State of the Art
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Unstable Angina and Non–ST Elevation Myocardial Infarction
Glenn N. Levine et al. JACC 2016;68:
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
Section F: Clinical guidelines
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Acute Coronary Syndrome (1)
What oral antiplatelet therapy would you choose?
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
Train-the-Trainer Cases
Management of AMI in patients presenting with STEMI
Train-the-Trainer Cases
Train-the-Trainer Cases
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

Cangrelor Case Presentations Gary L. Schaer, MD FACC, FAHA, FSCAI Professor of Medicine (Interventional Cardiology) Director, Cardiology Research Rush University Medical Center Chicago IL

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company Names

Gary L. Schaer MD Disclosure: Consultant; Advisory Board   Consultant; Advisory Board The Medicines Company AstraZeneca

55 yo man with chest pain

Pre-angiography Troponin <0.01 Glucose 182 mg/dL; HbA1C 6.7% STEMI page activated Aspirin 325 mg po No preloading with P2Y12 inhibitor

Right Coronary Angiography

EKG ACS Management Pathway STEMI Pathway NSTE-ACS Pathway Patient presents with symptoms of ACS EKG No ST-elevation ST-elevation ACS Management Pathway NSTE-ACS Pathway Aspirin 325 mg po or chewed + UFH (not LMWH) DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY STEMI Pathway Aspirin 325 mg po or chewed Emergency transfer to cath lab DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY Ischemia-Guided Strategy (low risk) Low risk TIMI score (0-1), GRACE (<109) Low risk trop neg female patients Patient or clinician preference in absence of high-risk features Stress test (if + => Cath) Early Invasive Strategy (intermediate to high risk) DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY Unfractionated heparin and anti-ischemic therapy Immediate Invasive Cath <2h Refractory or recurrent angina despite Med Rx Severe HF, unstable hemodynamics, malignant arrhythmias Early Invasive Cath <24h No “immediate invasive” features GRACE score >140 Temporal change in Trop New ST-seg depression Delayed Invasive Cath 25-72hs GFR <60 mL/min/1.73m2 EF <40% Early post-MI angina PCI within 6mo or CABG GRACE 109-140 or TIMI >2 Coronary Angiography -> PCI At start of PCI consider cangrelor (bolus + 2hr infusion) + anticoagulant (bivalirudin or UFH) Transition to oral P2Y12 therapy (if surgery not planned prior to discharge): ticagrelor 180 (begin during cangrelor infusion), or clopidogrel 600 mg (must begin immediately after cangrelor d/c).

PCI of 100% Mid-RCA Femoral access; 4-R Judkins guider Begin cangrelor 30 mcg IV loading dose, 4 mcg/kg/min continuous infusion to continue for 2 hours Begin bivalirudin PTCA 2.5 x 15 balloon IVUS for precise sizing 3.5 x 15mm Resolute DES deployed in mid-RCA IVUS confirms full stent expansion Ticagrelor withheld until completion of diagnostic left coronary angiogram

PCI of 100% Mid-RCA Femoral access; 4-R Judkins guider Begin cangrelor 30 mcg IV loading dose, 4 mcg/kg/min continuous infusion to continue for 2 hours Begin bivalirudin

Initial PTCA of 100% RCA

Post PTCA Result

Post DES Deployment

PCI of 100% Mid-RCA PTCA 2.5 x 15 balloon IVUS for precise sizing 3.5 x 15mm Resolute DES deployed in mid-RCA IVUS confirms full stent expansion Ticagrelor withheld until completion of diagnostic left coronary angiogram

Left coronary angiography

Left coronary angiography

Left coronary angiography

Left coronary angiography 90% proximal LAD with involvement of a bifurcating diagonal branch with a 70% at origin; LAD diffusely diseased with a large territory (wraps around apex) 70% ostial OM3, 90% distal circumflex (TIMI-2 flow) Films reviewed with heart team; decision made to proceed with CABG (plan for LIMA to LAD, SVG to diagonal, SVG to OM3 sequential to OM4) No P2Y12 inhibitor given Bivalirudin and cangrelor discontinued in cath lab Patient transported to OR for urgent CABG

Post CABG CABG surgery completed with no bleeding problems The patient was loaded with 180 mg of ticagrelor after transfer to the surgical ICU Additional medication started: atorvastatin 80mg po, lisinopril 10mg po, and metformin Ticagrelor 90 bid, aspirin 81 mg continued post-op (plan to continue for 4 years post-MI) Patient discharged on post-op day 5 to follow-up with cardiac surgeon and interventional cardiologist in 1-2 weeks Cardiac rehab recommended

46 yo Man with Chest Pain No prior medical history Presents to Rush ED with intermittent “burning” substernal chest pain and SOB for 2-3 days. Smokes 2 packs/day; construction worker No family history of CAD and no other known medical problems Has not seen a doctor in “many years”

EKG

Pre-angiography Troponin 0.14 (normal <0.10) Interventional service consulted by ED – urgent coronary angiogram recommended Aspirin 325 mg po Unfractionated heparin IV No preloading with P2Y12 inhibitor

Coronary Angiography

EKG ACS Management Pathway STEMI Pathway NSTE-ACS Pathway Patient presents with symptoms of ACS EKG No ST-elevation ST-elevation ACS Management Pathway NSTE-ACS Pathway Aspirin 325 mg po or chewed + UFH (not LMWH) DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY STEMI Pathway Aspirin 325 mg po or chewed Emergency transfer to cath lab DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY Ischemia-Guided Strategy (low risk) Low risk TIMI score (0-1), GRACE (<109) Low risk trop neg female patients Patient or clinician preference in absence of high-risk features Stress test (if + => Cath) Early Invasive Strategy (intermediate to high risk) DO NOT GIVE TICAGRELOR OR CLOPIDOGREL BEFORE CORONARY ANGIOGRAPHY Unfractionated heparin and anti-ischemic therapy Immediate Invasive Cath <2h Refractory or recurrent angina despite Med Rx Severe HF, unstable hemodynamics, malignant arrhythmias Early Invasive Cath <24h No “immediate invasive” features GRACE score >140 Temporal change in Trop New ST-seg depression Delayed Invasive Cath 25-72hs GFR <60 mL/min/1.73m2 EF <40% Early post-MI angina PCI within 6mo or CABG GRACE 109-140 or TIMI >2 Coronary Angiography -> PCI At start of PCI consider cangrelor (bolus + 2hr infusion) + anticoagulant (bivalirudin or UFH) Transition to oral P2Y12 therapy (if surgery not planned prior to discharge): ticagrelor 180 (begin during cangrelor infusion), or clopidogrel 600 mg (must begin immediately after cangrelor d/c).

PCI of Ostial LAD Femoral access - 90% ostial LAD – no other significant CAD Begin cangrelor 30 mcg IV loading dose, 4 mcg/kg/min continuous infusion to continue for 2 hours Begin bivalirudin 3.5 L-EBU guide; PTCA 2.5 x 15 balloon IVUS for precise sizing 4.0 x 15mm Xience DES deployed at LAD ostium IVUS to confirm full stent expansion

Stent Position at LAD Ostium

Post Stent Deployment

Post-PCI Load with 180 mg of ticagrelor po D/C bivalirudin Continue cangrelor until infusion complete (2 hours from start of infusion) Transfer to CCU Discharge in AM on ticagrelor + aspirin 81mg (plan for DAPT to continue for at least 1 year), atorvastatin 80mg Smoking cessation counseling Cardiac rehab recommended Follow-up in 1-2 weeks with interventional cardiologist

55 yo Man with Chest Pain 55 yo Asian man presents with “severe” left precordial chest pain that came on while running to catch a train Chest pain associated with shortness of breath, nausea and diaphoresis 911 called and patient brought to Rush ED; symptoms improved with nitro SL and morphine Past medical history Diabetes mellitus type 2 – “diet controlled” Hypertension – no meds Hyperlipidemia – no meds Non-smoker